Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
Specificity
This antibody detects endogenous levels of Bcr only when phosphorylated at Tyrosine 177.
Purification
Affinity Chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
Immunogen
The antiserum was produced against synthesized phosphopeptide derived from Human Bcr around the phosphorylation site of Tyrosine 177 (P-F-Yp-V-N).
Suitable for use in Western blot (1/500-1/1000) and Immunohistochemistry onParaffin-Embedded Sections (1/50-1/100). Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.0 mg/mL
Buffer
PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % Sodium Azide and 50 % Glycerol
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
The breakpoint cluster region protein (Bcr) is best know to be involved in genomic translocation with fusion partner Abl (Cbr-Abl) causing chronic myelogenous leukemia (CML). This 160 kDa protein contains a serine/threonine kinase domain, an SH2 binding domain, a GTP/GDP exchange domain and a C-term domain which functions as a GTPase activating protein for p21rac and CDC42. Additionally, Bcr is involved in signal transduction and can down regulate Ras mediated cell signaling.Synonyms: BCR1, Breakpoint cluster region protein, D22S11, NY-REN-26, Renal carcinoma antigen NY-REN-26